345 related articles for article (PubMed ID: 30891428)
1. The Value of Liquid Biopsies for Guiding Therapy Decisions in Non-small Cell Lung Cancer.
Saarenheimo J; Eigeliene N; Andersen H; Tiirola M; Jekunen A
Front Oncol; 2019; 9():129. PubMed ID: 30891428
[TBL] [Abstract][Full Text] [Related]
2. Unlocking the future of cancer diagnosis - promises and challenges of ctDNA-based liquid biopsies in non-small cell lung cancer.
Reina C; Šabanović B; Lazzari C; Gregorc V; Heeschen C
Transl Res; 2024 Jun; 272():41-53. PubMed ID: 38838851
[TBL] [Abstract][Full Text] [Related]
3. Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review.
Tomasik B; Skrzypski M; Bieńkowski M; Dziadziuszko R; Jassem J
Transl Lung Cancer Res; 2023 Mar; 12(3):594-614. PubMed ID: 37057121
[TBL] [Abstract][Full Text] [Related]
4. Current status and future perspectives of liquid biopsy in non-small cell lung cancer.
Chang S; Hur JY; Choi YL; Lee CH; Kim WS
J Pathol Transl Med; 2020 May; 54(3):204-212. PubMed ID: 32460474
[TBL] [Abstract][Full Text] [Related]
5. The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring.
Bracht JWP; Mayo-de-Las-Casas C; Berenguer J; Karachaliou N; Rosell R
Curr Oncol Rep; 2018 Jul; 20(9):70. PubMed ID: 30030656
[TBL] [Abstract][Full Text] [Related]
6. Liquid biopsy in non-small cell lung cancer: a key role in the future of personalized medicine?
Pi C; Zhang MF; Peng XX; Zhang YC; Xu CR; Zhou Q
Expert Rev Mol Diagn; 2017 Dec; 17(12):1089-1096. PubMed ID: 29057681
[TBL] [Abstract][Full Text] [Related]
7. Critical issues in the clinical application of liquid biopsy in non-small cell lung cancer.
Manicone M; Poggiana C; Facchinetti A; Zamarchi R
J Thorac Dis; 2017 Oct; 9(Suppl 13):S1346-S1358. PubMed ID: 29184673
[TBL] [Abstract][Full Text] [Related]
8. The Role of the Liquid Biopsy in Decision-Making for Patients with Non-Small Cell Lung Cancer.
Akhoundova D; Mosquera Martinez J; Musmann LE; Britschgi C; Rütsche C; Rechsteiner M; Nadal E; Garcia Campelo MR; Curioni-Fontecedro A
J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33207619
[TBL] [Abstract][Full Text] [Related]
9. Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung Cancer.
Schrock AB; Welsh A; Chung JH; Pavlick D; Bernicker EH; Creelan BC; Forcier B; Ross JS; Stephens PJ; Ali SM; Dagogo-Jack I; Shaw AT; Li T; Ou SI; Miller VA
J Thorac Oncol; 2019 Feb; 14(2):255-264. PubMed ID: 30368012
[TBL] [Abstract][Full Text] [Related]
10. Using circulating cell-free DNA to monitor personalized cancer therapy.
Oellerich M; Schütz E; Beck J; Kanzow P; Plowman PN; Weiss GJ; Walson PD
Crit Rev Clin Lab Sci; 2017 May; 54(3):205-218. PubMed ID: 28393575
[TBL] [Abstract][Full Text] [Related]
11. Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients.
Francaviglia I; Magliacane G; Lazzari C; Grassini G; Brunetto E; Dal Cin E; Girlando S; Medicina D; Smart CE; Bulotta A; Gregorc V; Pecciarini L; Doglioni C; Cangi MG
Lung Cancer; 2019 Aug; 134():225-232. PubMed ID: 31319985
[TBL] [Abstract][Full Text] [Related]
12. Liquid Biopsies in a Veteran Patient Population With Advanced Prostate and Lung Non-Small Cell Carcinomas: A New Paradigm and Unique Challenge in Personalized Medicine.
Dalal S; Petersen J; Jhala D
Fed Pract; 2021 Jan; 38(1):8-14. PubMed ID: 33574643
[TBL] [Abstract][Full Text] [Related]
13. Understanding the Mechanisms of Resistance in
Del Re M; Crucitta S; Gianfilippo G; Passaro A; Petrini I; Restante G; Michelucci A; Fogli S; de Marinis F; Porta C; Chella A; Danesi R
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31416192
[TBL] [Abstract][Full Text] [Related]
14. Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer.
Levy B; Hu ZI; Cordova KN; Close S; Lee K; Becker D
Oncologist; 2016 Sep; 21(9):1121-30. PubMed ID: 27388233
[TBL] [Abstract][Full Text] [Related]
15. Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC.
Rolfo C; Mack PC; Scagliotti GV; Baas P; Barlesi F; Bivona TG; Herbst RS; Mok TS; Peled N; Pirker R; Raez LE; Reck M; Riess JW; Sequist LV; Shepherd FA; Sholl LM; Tan DSW; Wakelee HA; Wistuba II; Wynes MW; Carbone DP; Hirsch FR; Gandara DR
J Thorac Oncol; 2018 Sep; 13(9):1248-1268. PubMed ID: 29885479
[TBL] [Abstract][Full Text] [Related]
16. The Role of Serial Liquid Biopsy in the Management of Metastatic Non-Small Cell Lung Cancer (NSCLC).
Sama S; Le T; Ullah A; Elhelf IA; Kavuri SK; Karim NA
Clin Pract; 2022 Jun; 12(3):419-424. PubMed ID: 35735665
[TBL] [Abstract][Full Text] [Related]
17. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.
Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P
Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141
[TBL] [Abstract][Full Text] [Related]
18. Liquid Biopsy in Lung Cancer: Clinical Applications of Circulating Biomarkers (CTCs and ctDNA).
Lim M; Kim CJ; Sunkara V; Kim MH; Cho YK
Micromachines (Basel); 2018 Feb; 9(3):. PubMed ID: 30424034
[TBL] [Abstract][Full Text] [Related]
19. Non-invasive urine testing of EGFR activating mutation and T790M resistance mutation in non-small cell lung cancer.
Berz D; Raymond VM; Garst JH; Erlander MG
Exp Hematol Oncol; 2015; 5():24. PubMed ID: 27508108
[TBL] [Abstract][Full Text] [Related]
20. Utility of Liquid Biopsy by Improved PNA-LNA PCR Clamp Method for Detecting EGFR Mutation at Initial Diagnosis of Non-Small-Cell Lung Cancer: Observational Study of 190 Consecutive Cases in Clinical Practice.
Ito K; Suzuki Y; Saiki H; Sakaguchi T; Hayashi K; Nishii Y; Watanabe F; Hataji O
Clin Lung Cancer; 2018 Mar; 19(2):181-190. PubMed ID: 29174086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
